- Current report filing (8-K)
2009年3月18日 - 6:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 12, 2009
Synovics Pharmaceuticals, Inc.
|
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
|
|
0-22011
|
|
86-0760991
|
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
incorporation)
|
|
|
|
|
|
|
5360 Northwest 35th Avenue, Ft. Lauderdale, FL
|
|
33309
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrants telephone number, including area code
(954) 486-4590
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 4.01
Changes in Registrants Certifying Accountant
On February 12, 2009, Miller, Ellin & Company, LLP (
Miller Ellin
), the Registrants independent
accountant and the principal accountant engaged to audit its financial statements, notified the Registrant that it consummated a merger (the
Merger
) of its practice
into the practice of Rosen Seymour Shapss Martin & Company LLP (
Rosen Seymour
), with Rosen Seymour the resulting surviving legal entity, such Merger effective
as of January 1, 2009. As of the date of the Merger, Rosen Seymour, as a matter of law, succeeded Miller Ellin as the Registrants independent accountants, and the Registrant formally engaged Rosen Seymour, as successor in interest of Miller
Ellin, as its new independent accountant and principal accountant to audit its financial statements. The foregoing change in auditor was approved by the Registrants board of directors.
The
audit report of Miller Ellin on the Registrants financial statements for
the fiscal years ended October 31, 2007 and October 31, 2008 expressed an unqualified
opinion and included an explanatory paragraph relating to the Registrants
ability to continue as a going concern. Such audit reports did not contain any
other adverse opinion or disclaimer of opinion or qualification. During Registrants
two most recent fiscal years and the period from the end of the most recently
completed fiscal year through the date of the Merger, there were no disagreements
with Miller Ellin on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedure, which, if not resolved to
the satisfaction of Miller Ellin, would have caused such entity to make reference
to such disagreements in its reports. During the Registrants two most
recent fiscal years and through the date of the Merger, no
reportable events (as described in Item 304(a)(1)(v) of Regulation
S-K) occurred that would be required by Item 304(a)(1)(v) to be disclosed in
this report.
During
Registrants two most recent fiscal years and the period from the end of the most recently completed fiscal year through the date of the Merger, neither the Registrant nor anyone on its behalf
consulted Rosen Seymour regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrants financial statements, and
either a written report was provided to the Registrant or oral advice was provided that Rosen Seymour concludes was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing or financial reporting issue,
or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to such item) or reportable events (as described in Item 304(a)(1)(v) of
Regulation S-K).
The Registrant has requested Miller Ellin and Rosen Seymour to review the disclosures contained in this report and have asked each of them to furnish the Registrant with a currently dated
letter addressed to the SEC containing any new information, clarification of the expression of the Registrants views or the respects in which it does not agree with the statements made by it in response to Item 304(a) of Regulation S-K. A copy
of each such letter is filed as an exhibit to this report.
Item 9.01.
Financial Statements and Exhibits
(a)
|
Not applicable.
|
|
(b)
|
Not applicable.
|
|
(c)
|
Not applicable.
|
|
(d)
|
Exhibits
|
|
|
|
16.1
|
Letter dated March 17, 2009, from Miller Ellin & Company, LLP to the Securities and Exchange Commission
|
|
|
16.2
|
Letter dated March 17, 2009, from Rosen Seymour Shapss Martin & Company LLP to the Securities and Exchange Commission
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 17, 2009
SYNOVICS PHARMACEUTICALS,
INC.
|
|
By:
|
|
/s/
Mahendra
Desai
|
Name:
|
Mahendra Desai
|
Title:
|
Chief Financial Officer
|
Synovics Pharmaceuticals (CE) (USOTC:SYVC)
過去 株価チャート
から 1 2025 まで 2 2025
Synovics Pharmaceuticals (CE) (USOTC:SYVC)
過去 株価チャート
から 2 2024 まで 2 2025